Small molecule PI3K-inhibitors are approved for the treatment of lymphomas and chronic lymphatic leukaemia and are currently evaluated in solid tumours e.g. breast cancer [27] and NSCLC [28]. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.